• Vaccine Name: Leishmania vaccine using recombinant L. tarentolae strain expressing A2 antigen
• Target Pathogen: Leishmania donovani
• Target Disease: Visceral leishmaniasis
• Vaccine Ontology ID: VO_0004180
• Type: Recombinant vector vaccine
• Status: Research
• Antigen: mouse
• A2 gene engineering:
  • Type: Recombinant protein preparation
  • Description:
  • Detailed Gene Information: Click Here.
• Immunization Route: Intraperitoneal injection (i.p.)

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: In the case of i.p. immunization, total number of 5 × 10^6 stationary-phase promastigotes were used. Mice were immunized with L. tarentolae expressing the GFP only as a control and another group were immunized with recombinant L. tarentolae-A2 (Mizbani et al., 2009).
• Challenge Protocol: Six weeks after immunization, animals were challenged with 10^7 virulent stationary-phase L. infantum promastigotes through the lateral tail vein (Mizbani et al., 2009).
• Efficacy: Study results show that a single intraperitoneal administration of the A2-recombinant L. tarentolae strain expressing the Leishmania donovani A2 antigen protects BALB/c mice against L. infantum challenge and that protective immunity is associated with high levels of IFN-gamma production prior and after challenge (Mizbani et al., 2009).